Cancer Breakthroughs. Realized. We help transform groundbreaking cancer-related research and innovation in Ontario into viable commercial opportunities that benefit patients, researchers, investors and Ontario's economy.

FACIT Builds on Commercialization Momentum by Attracting Experienced Executive-in-Residence

Anil Amlani expands FACIT’s oncology expertise in medical device sector

Anil Amlani joins FACIT with strong executive and transactional experience, broadening the available expertise to provide critical senior management and leadership to create and nurture FACIT start-ups in Ontario.

First Patient Treated in Turnstone's Lung Cancer Trial Combining Novel Viral Cancer Therapy with Approved Checkpoint Inhibitor

Combination of Turnstone's oncolytic viral immunotherapy with checkpoint inhibitors showed promising results in preclinical testing.

Turnstone announced that treatment has been initiated on the first patient in the company's Phase I/II clinical trial combining its novel oncolytic viral immunotherapy agent, MG1-MAGEA3, with pembrolizumab, an approved anti-PD-1 antibody.

FACIT Announces Investment in Propellon Therapeutics

Seed financing of CAD$3.0M positions first-in-class WDR5 cancer therapy for clinical development.

Seed funding from FACIT enables Propellon to accelerate the nomination of a candidate drug and position the Company for financing and/or entering a strategic partnership for clinical trials in patients with haematological cancers.  

FACIT Launches The Prospects Oncology Fund

New evergreen fund to help Ontario discoveries reach seed-stage funding faster.

FACIT announces the launch of The Prospects Oncology Fund, designed to advance early-stage Ontario cancer discoveries by supporting the proof-of-concept studies needed to attract seed-stage investment.

FACIT-Seeded Fusion Pharmaceuticals Closes US$25M Series A Led by Johnson & Johnson Innovation

Financing leverages and strengthens Ontario’s next-generation radiotherapeutics expertise, products.

FACIT and OICR report that Fusion Pharmaceuticals Inc. has closed a US$25M Series A financing, with Johnson & Johnson Innovation – JJDC, Inc. as the lead investor. Additionally, new investors include venture groups HealthCap, TPG Biotechnology Partners, and Genesys Capital, as well as founding investor FACIT.

Triphase Accelerator Announces New Product Option Deal with Celgene

The new collaboration provides Celgene with an option to acquire all Triphase Accelerator’s assets relating to TRPH 222 (CD22-4AP), an antibody-drug conjugate in development for lymphoma.

Triphase Accelerator Corporation announced a new strategic collaboration with Celgene Corporation, that provides Celgene with an option to acquire all Triphase Accelerator’s assets relating to TRPH 222 (CD22-4AP), an antibody-drug conjugate in development for lymphoma.

Triphase Accelerator Announces Acquisition of its First Compound, Marizomib, by Celgene Corporation

Marizomib is a novel brain-penetrant proteasome inhibitor in development for patients with glioblastoma and relapsed and/or refractory multiple myeloma

Triphase Accelerator Announces that Celgene Corporation has acquired the company's assets related to its proteasome inhibitor, marizomib, which is in development for glioblastoma and relapsed and/or refractory multiple myeloma.

FACIT Start-up Turnstone Biologics Closes USD $41M Financing

OrbiMed, Versant-led round continues commercialization success for Turnstone’s cancer therapies

FACIT-created Turnstone Biologics raises USD $41M, one of the largest Series B rounds for a Canadian biotech, attracting blue-chip healthcare investors to accelerate commercialization of proprietary oncolytic viral immunotherapies.

Catalent Biologics and Triphase Accelerator Corporation Announce License Agreement to Advance SMARTag™ ADC to Clinic

Triphase will obtain worldwide rights to further develop Catalent's proprietary CD22-4AP Antibody-Drug Conjugate (ADC), which has been developed by Catalent’s wholly owned subsidiary, Redwood Bioscience, Inc., using its SMARTag™ technology platform.

Propellon Therapeutics to Accelerate WDR5 Inhibitor Development for Cancers

FACIT forms biotechnology company for OICR-discovered first-in-class epigenetic modifiers

The creation of Propellon to manage the development and commercialization of a portfolio of first-in-class epigenetic therapeutics, WDR5 inhibitors, enables important development activities including attracting private sector investment and industry partnerships.